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Objective. Fatty liver is a rising global health concern, significantly increasing the burden of health care cost. Nonalcoholic fatty
liver disease (NAFLD) has a correlation with metabolic syndrome and its complications. Method. We reviewed the literature
regarding the mechanisms of developing NAFLD through AGE-RAGE signaling. Results. NAFLD, metabolic syndrome, and
production of advanced glycation end-products (AGEs) share many common risk factors and appear to be connected. AGE
induces production of the receptor for AGE (RAGE). AGE-RAGE interaction contributes to fat accumulation in the liver leading
to inflammation, fibrosis, insulin resistance, and other complications of the fatty liver disease. ,e immune system, especially
macrophages, has an important defense mechanism against RAGE pathway activities. Conclusion. Soluble form of RAGE
(sRAGE) has the capability to reduce inflammation by blocking the interaction of AGE with RAGE. However, sRAGE has some
limitations, and the best method of usage is probably autotransplantation of transfected stem cells or monocytes, as a precursor of
macrophages and Kupffer cells, with a virus that carries sRAGE to alleviate the harmful effects of AGE-RAGE signaling in the
settings of fatty liver disease.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) refers to the
presence of hepatic steatosis in absence of substantial alcohol
consumption or any other underlying causes of liver disease
[1, 2]. It is a global health burden and is not only the most
common cause of chronic liver disease in the United States
but also affects middle- and low-income countries, affecting
up to one-third of the adult population [3–5].
NAFLD has a wide clinical and pathological spectrum and
ranges from simple fat deposition, nonalcoholic steatohe-
patitis (NASH), hepatocyte necrosis, and inflammation with
or without fibrosis, to the end-stage liver disease that may
need liver transplantation [1, 2]. Although the pathogenesis of
NAFLD is not completely elucidated, hepatic steatosis seems
to be an inciting event subsequently leading to inflammation,
cell injury, and distortion of the cellular structure through
micro- and macrovascular mechanisms [2, 6].
Risk factors for NAFLD are almost the same as risk
factors for metabolic syndrome and include central obesity,
insulin resistance, dysglycemia, dyslipidemia, and hyper-
tension [7]. Dietary factors like increased intake of refined
sugars, fructose, saturated fat, and cholesterol as well as
decreased intake of polyunsaturated fatty acids especially
omega 3 as opposed to omega 6 has been related to NAFLD
progression [7, 8]. Because of its etiopathogenic similarities
with metabolic syndrome, NAFLD is also considered as the
hepatic component of metabolic syndrome [9].
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,e majority of patients with NAFLD are asymptomatic
but can present with nonspecific symptoms such as fatigue,
early satiety, and malaise; however, it lacks clear causality
[10]. Hepatomegaly can be seen in the advanced stage, and
eventually, symptoms and signs of chronic liver disease and
portal hypertension ensue [11, 12].
NAFLD is diagnosed by evidence of fat accumulation in
the liver by either histologic or imaging findings [5]. ,e
histologic threshold is fat deposition in at least 5% of he-
patocytes [13]. Although transabdominal sonography is the
most commonly used testing modality with a sensitivity and
specificity of 85% and 95%, respectively, it requires a higher
fat accumulation (Up to 20–30%) for diagnosis and has high
inter- and intraobserver variation [14]. ,e most accurate
imaging for evaluation of fat deposition is T1-weighted dual-
echo magnetic resonance (MR) image and proton magnetic
resonance spectroscopy [15, 16]. ,e gold standard for di-
agnosis of inflammation and fibrosis is liver biopsy [14, 17].
,e fibrosis (FIB)-4 score and NAFLD fibrosis score which
are based on age, serum liver enzymes, serum albumin
content, platelet count, and anthropometric measures and
presence of diabetes mellitus have shown promise in
detecting patients with fibrosis among those suffering from
simple steatosis [15, 18].
Patients with NAFLD may progress to NASH, cirrhosis,
and decompensation in long term [15, 19]. It is also con-
sidered a multisystem disease affecting not only the liver but
also the heart and kidney among others [20–22]. Although
the progression seems to be secondary to environmental
factors and exposure to advanced glycation end-products
(AGEs), its possibility, as well as the rate of progression, has
remained a matter of debate [2, 6].
In this review, a brief discussion regarding the patho-
physiology of NAFLD and the role of AGEs in the devel-
opment and progression of NAFLD into NASH, cirrhosis,
and hepatocellular carcinoma has been collected. Finally, we
will debate the current opportunities to prevent and/or treat
NAFLD and AGE-related liver injury and propose a po-
tential therapeutic approach.
2. The Process of AGE, RAGE, and
sRAGE Production
Diet plays an important role in the development of NAFLD.
Typical dietary pattern of NAFLD patients consists of in-
creased consumption of saturated fatty acid-, cholesterol-,
and fructose-rich products. Polyunsaturated fatty acids
(PUFAs) and antioxidants have protective roles against
NAFLD development [23]. On the contrary, increased in-
take of fructose and fat-processed foods containing saturated
fatty acids are the major sources of endogenous advanced
glycation end-products (AGEs). [23, 24]. Based on the
correlation between high fat/carbohydrate diets with
NAFLD and AGEs production and the protective roles of
antioxidants and diets containing PUFA, AGE production
may play a crucial role in the onset and progression of
NAFLD. Furthermore, aging, type 2 diabetes mellitus,
obesity, and metabolic syndrome are reported as risk factors
of developing NAFLDwhich have association with increased
AGE production [23, 25, 26].
,ree different pathways participate in endogenous
generation of AGEs including nonenzymatic glycation, the
polyol pathway, and lipid peroxidation. ,e process of AGE
accumulation usually takes place in the setting of hyper-
glycemia; however, other conditions such as aging, in-
flammation, renal failure, oxidative stress, consumption of
high fat diet or processed food, excessive alcohol con-
sumption, and cigarette smoking can increase endogenous
or exogenous production of AGEs. ,e initial reaction starts
with a nonenzymatic reaction between the reactive carbonyl
group of reducing sugar (such as glucose, fructose, glycer-
aldehyde or carbonyl compounds, and acetaldehyde) and a
free amino group on proteins. ,e reaction is reversible,
produces a Schiff’s base, and then undergoes spontaneous
rearrangement resulting in a partially reversible Amadori
product. ,e nonenzymatic glycation (Maillard) reaction
can also happen between reducing sugar and the other
macromolecules (lipids and nucleic acids); however, in
human subjects with diabetes, the Maillard reaction mainly
occurs between sugar, lysine, and arginine amino acid
residues. Initially produced AGEs will undergo further
modification, which leads to the production of heteroge-
neous chemical structures that can be found in different
tissues and even plasma. AGE accumulation in the tissues
affects proteolysis leading to increase in oxidized and
damaged proteins, induction of inflammation, increase in
reactive oxygen species production, and finally affecting
cellular metabolic activities, which may further perpetuate
AGE production (Figure 1) [23, 25].
AGEs not only have direct prooxidant and proin-
flammatory effects but also interact with variable cell surface
receptors including receptor for AGEs (RAGE), scavenger
receptors including class A, class B (CD36), class E (LOX-1),
and class H (FEELs), and AGE receptor complexes (AGE-R).
AGEs also induce production of RAGE, leading to initiation
of different intrinsic signaling pathways consisting of PKC,
PI3K/Akt, Src/RhoA, JAK/STAT, MAPK/ERK, and
NADPH oxidase. Activation of these intrinsic signal path-
ways results in higher levels of NF-κB, Egr-1, and/or other
transcription factors which upregulate inflammation, oxi-
dative injury affecting cellular motility, adhesion, and
metabolism, ultimately causing tissue injury [24, 25, 27]. In
addition, the AGE/RAGE signaling pathway can also acti-
vate apoptosis through caspase family (Figure 2) [28, 29].
RAGE is a structurally like immunoglobulin. It has
extracellular portion containing V-C1-C2 domains, trans-
membrane domain, and intracellular domain.,e V domain
interacts with RAGE ligands. ,e cytoplasmic domain of
RAGE interacts with diaphanous-1, which is required to
activate the postreceptor signaling pathways [30]. DIAPH1
is a type of formin which is principally involved in cyto-
skeleton, interacts withmicrotubules, and plays a crucial role
in cell organelles kinetics [31]. ,e interaction between
DIAPH1 (mDia1) with RAGE stabilizes RAGE on cell
membranes (Figure 3).
,e RAGE can be expressed in different tissues and cell
types including immune system cells monocyte/
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macrophage, lymphocyte, and neutrophil, endothelial cells,
smooth muscle cells, and hepatocytes where it interacts with
variable ligands [1, 23, 25].,e RAGE ligands include AGEs,
HMGB1 (high mobility group box 1), LPS (lipopolysac-
charides), S100/calgranulins, amyloid-β peptide (Aβ), and
other forms of amyloid, lysophosphatidic acid (LPA),
macrophage adhesion ligand-1 (MAC-1), and complement
component 1q (C1q) (Figures 2 and 3) [23, 24, 27].
AGEs mediated pathways can be inhibited through AGE-Rs
or CD36. While AGE-R detoxifies AGEs, CD36 mediates
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Figure 1: ,e cycle of AGE production [23].
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Figure 2: ,e process of AGE formation, RAGE-ligands interaction, and related consequences. CML, pentosidine, argpyrimidine,
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endocytosis ofAGEs, leading to intracellular degradation through
lysosome and is eventually cleared by the kidneys [23, 24].
RAGE signaling pathway can be potentially inhibited by
different mechanisms. First, enzymatic cleavage of RAGE
(cRAGE) by ADAM10 (a disintegrin and metalloproteinase
domain-containing protein 10) and matrix metalloproteinase
(MMPs) disrupts the external domain of the RAGE and leads
to the production of soluble RAGE (sRAGE) which is a
natural defense tool against AGEs. sRAGE can attach to AGEs
and block AGE-RAGE interaction. sRAGE contains the ex-
tracellular portion (V-C1-C2 domains) of RAGE molecules
and can be measured by the ELIZA method [25, 32]. AGEs
can potentially increase production and activity of matrix
metalloproteinase activity which technically reduces RAGE
signaling activities and increases sRAGE production [33, 34].
Second, endogenous secretory RAGE (esRAGE) which is
produced by alternatively spliced pre-mRNA of AGER gene is
another form of soluble RAGE that can block AGE-RAGE
interaction (Figure 3) [25, 32].
3. AGE-RAGE Interaction and Development of
Fatty Liver
NAFLD is associated with obesity and diabetes. Liver plays a
crucial role in glucose and lipid metabolism. Although the
exact pathogenesis of NAFLD has not been clarified, in-
flammation, oxidant injury, apoptosis, and cell proliferation
are the known events in NAFLD which are interconnected
with glucose and lipid metabolism. ,e onset and devel-
opment hepatic steatosis is linked with insulin resistance
[35]. In addition, the complex mixture of metabolic and
inflammatory signals causes the course of events from
obesity to diabetes, and RAGE signaling pathwaymight have
an important role [36].
,e spectrum of NAFLD spans from isolated fat de-
position (steatosis) to variable hepatocellular injury due to
inflammation with or without fibrosis (NASH). Triglyceride
(TG) turnover determines energy homeostasis in human.
Excess accumulation of TG in hepatocytes due to increased
uptake or de novo synthesis of fatty acids (FA) is an im-
portant reason for development of NAFLD [37]. In addition,
increased dietary intake of cholesterol can promote fatty
liver and inflammation due to mitochondrial dysfunction
[35]. Excess lipid storage seems to be an initial step for
hepatocellular damage. Overstorage of TG generally is as-
sociated with lipotoxicity which leads to cellular organelle
dysfunction and injury, ultimately resulting in obesity and
related diseases such as fatty liver, metabolic syndrome, and
diabetes. Recent literature indicates that lipotoxicity mainly
occurs by specific lipids such as free fatty acids (palmitic
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Figure 3: RAGE structure and the process of sRAGE formation.
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acid), diacylglycerols, cholesterol, ceramides, and lyso-
phosphatidylcholine. Lipotoxicity causes unbalanced energy
metabolism that progresses through different cellular sig-
naling cascades including endoplasmic reticulum (ER)
stress, mitochondrial dysfunction, induction of oxidative
stress, and finally leading to inflammation and cellular
apoptosis [37, 38].
,e inflammation, cellular proliferation, and increased
oxidative stress caused by AGEs lead to progression of
NAFLD from simple steatosis to NASH and fibrosis [39]. On
the contrary, oxidative stress and inflammation can also
cause AGE production [1]. As AGEs induce RAGE signaling,
the activated RAGE signaling pathway further induces ox-
idative stress and inflammation [23, 40]. ,e correlation
between RAGE signaling pathway with oxidative stress and
inflammation is therefore of a cyclic causation.
RAGE plays an important role in connecting innate and
adaptive immune system as well as participates in the onset
and maintenance of inflammation [41]. It facilitates cellular
adhesion and migration of white blood cells and interacts
with some of the released proinflammatory molecules such
as HMBG1 and calgranulin/S100 family [42]. Mice exper-
iments have shown that a high fat diet induces the in-
flammatory response leading to increase in the
concentration of RAGE ligands in the liver. In addition,
knocking out RAGE attenuates the effects of high fat diet on
hepatic glucose production and improves insulin function in
the liver [36].
,e rate of cell death in the rat liver with diabetes is
directly correlated to oxidative stress and expression of
HMBG1 which ultimately regulates the cross-talk between
apoptosis and autophagy [43]. ,e rate of progression of
liver disease from NAFLD to fibrosis is higher among pa-
tients with elevated blood glucose levels, which can be at-
tributed to excess AGEs and RAGE production among these
groups of patients [44, 45]. ,is signifies the importance of
AGEs having a direct involvement in progression of NAFLD
through interaction with RAGE [46].
,is signifies importance of AGE-RAGE signaling as an
important cause of development and progression of NAFLD
from simple fat deposition in hepatocytes to development of
extensive liver fibrosis.
4. AGE-RAGE Signaling and Development of
Insulin Resistance in NAFLD
Obesity and insulin resistance are the two most important
contributors to the development of metabolic syndrome and
NAFLD. Insulin regulates glucose and lipid metabolism.
Hepatic insulin resistance is considered as an important sign
or cause of NAFLD. Hepatic insulin resistance is defined as
impaired suppression of hepatic glucose production through
glycogenolysis and/or gluconeogenesis by insulin. It can
have several different mechanisms at the molecular level
including hyperglycemia with hyperinsulinemia, increased
free fatty acids, and their metabolites, oxidative stress, al-
tered profile of adipocytokines and formation of advanced
glycation end-products [47].
In addition, high fat diet and endogenous fatty acid
synthesis mediated by fatty acid synthase (FAS) are known
to be involved in macrophage-induced pathological insulin
resistance [48].
High fat diet and hyperglycemia increase formation and
accumulation of AGEs. Increased AGEs and its interaction
with its cellular receptor RAGE activate cascade of down-
stream cellular signaling and ultimately causing oxidative
stress and chronic inflammation [49]. High AGE levels can
also aggravate liver injury by not only the upregulation of
inflammation, oxidative stress, and cytokines synthesis but
also the activation of hepatic stellate cells that are involved in
fat storage and fibrosis [50]. AGEs also disrupt mitochon-
drial energy metabolism and therefore inhibit cellular
proliferation [43]. Glyoxal, which has been connected to
oxidative stress and leads to AGEs formation, can cause liver
mitochondrial dysfunction in a dose-dependent manner
[51]. It also interferes with lipid metabolism and functions of
antioxidants [52]. It seems that AGEs have a crucial role in
development of hepatic insulin resistance [47, 53, 54].
Furthermore, chronic hyperglycemia and hyperinsulinemia
also lead to downregulation of soluble form of RAGE
(sRAGE) which again enhances the AGE-RAGE cascade
leading to further insulin resistance [55].
Not only AGE-RAGE pathway leads to insulin re-
sistance, but de novo lipid accumulation in hepatocytes also
contribute to and can accentuate insulin resistance. Lipid
accumulation in hepatocytes impairs intracellular signal
transmission upon activation of insulin receptors leading to
insulin resistance [47, 56]. ,e molecular events comprise
progressive mitochondrial dysfunction and autophagy, in-
crease in toxic lipids derivative intermediates (diacylglycerol
-DAG- and ceramide), and decrease in total phosphati-
dylcholine, causing immune-mediated hepatocellular
damage, ultimately resulting in hepatic insulin resistance
[37, 56]. Hepatic insulin resistance also drives glucose into
lipogenesis instead of glycogen synthesis leading to further
hepatocyte lipid accumulation [57].
Despite strong association between AGE-RAGE sig-
naling, insulin resistance, and NAFLD, the process of
evolution from NAFLD to NASH, liver cirrhosis, and/or
hepatocellular carcinoma is not only influenced by obesity
and insulin resistance but also due to integrated interaction
of genes, environmental factors, gut microbiome, and im-
mune system [50]. However, presuming the correlation of
the same factors contributing to hepatic insulin resistance,
AGEs production, and activation of RAGE signaling, we
may consider a crucial role for AGE-RAGE signaling in the
development of hepatic insulin resistance due to NAFLD.
5. AGE-RAGE Signaling and Immune
Cells, Macrophages
RAGE expression on immune cells, including macrophages,
has been shown. High fat diet increases expression of RAGE
ligand in the liver and adipose tissue [36]. ,e level of AGER
mRNA is significantly higher in diabetic versus nondiabetic
monocytes from the peripheral blood of human subjects
[58]. AGEs have negative effects on the polarization and
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anti-inflammatory roles of M2 macrophages while aug-
menting the proinflammatory response of M1 macrophages
[59].
Furthermore, sRAGE, a RAGE ligand decoy, has a
promising result on reducing inflammation and pro-
longation of rat survival after acute liver failure and could
improve hepatocytes survival after ischemic reperfusion
injury [40, 60]. However, absence of RAGE on macrophages
or applying sRAGE can diminish macrophage phagocytosis
and clearance of apoptotic cells which is important for tissue
homeostasis and modulation of inflammation [61]. On the
contrary, transfection of bone marrow mesenchymal stem
cells or umbilical cord-derived mesenchymal stem cells by
sRAGE has more suppressive effects on inflammation and
improves cell survival [60, 62]. ,is probably means that the
transfected mesenchymal cells provide more accessible
sRAGE to the area of AGE-RAGE signaling without dis-
abling immune cells function. In other words, it seems that
the cross-talk between AGE-RAGE signaling and in-
flammation/insulin resistance is complex, and probably
initial activation of macrophages has beneficial effects, but
further activation can lead tomore inflammation and insulin
resistance.
6. sRAGE and Its Correlation with NAFLD
sRAGE competes with RAGE ligands in binding to RAGE on
cell membranes but does not initiate signal transduction,
and thereby, it has a protective role in NAFLD. ,e serum
levels of sRAGE in NAFLD patients are lower than the
general population, and its level correlates with severity of
hepatic steatosis, with higher levels of sRAGE in patients
with mild disease compared to patients with moderate-to-
severe hepatic steatosis [63]. Many articles have reported
correlation of sRAGE and/or esRAGE with various diseases
or conditions; however, the data are inconsistent. ,ere
appears to be a bidirectional correlation, which further
depends on the state and/or extent of the disease process. For
instance, sRAGE has a negative correlation with body mass
index (BMI) and rises with antidiabetic medications (thia-
zolidinediones) and after bariatric surgery [64–66]. Lower
levels of sRAGE are reported in atherosclerosis, hypercho-
lesterolemia, and hypertension, whereas higher levels are
found in patients with diabetes [27]. ,erefore, sRAGE
cannot be a reliable biomarker to assess the RAGE signaling
activities as it can be elevated in either excess RAGE pro-
duction or disruption. However, according to the fact that
AGEs induce ADAM10 secretion, AGEs/sRAGE ratio might
be helpful in the diagnosis of NAFLD patients (Table 1)
[67, 78, 79].
7. Current Treatment, Targeting RAGE, and
Future Direction
Despite significant improvement in the understanding and
knowledge of etiology and pathophysiology of NAFLD,
there is still no treatment modality which has been proven to
be successful in the treatment of NAFLD. Life-style modi-
fications, such as exercise and weight loss, remain the
cornerstone of treatment for patients with NAFLD and
NASH. Pharmacologic therapy is generally recommended
for biopsy-proven NASH and high-risk situations such as
liver cirrhosis and/or treating complications, such as di-
abetes, hypertension, or hyperlipidemia. Biguanide (met-
formin), peroxisome proliferator-activated receptor gamma
(PPAR-γ) agonists (pioglitazone), long-acting glucagon-like
peptide- (GLP-) 1 receptor agonist (liraglutide), vitamin E,
lipid-lowering agents (such as statins, ezetimibe, and
fibrates), antioxidants, pentoxifylline, angiotensin receptor
blockers (losartan), ursodeoxycholic acid (UDCA), symbi-
otic or probiotics, obeticholic acid (Farnesoid X receptor
agonist), and peroxisome proliferator-activated receptor
alpha (PPAR-α) agonist (Elafibranor) are currently available
medical therapy for treatment of NAFLD. Reduction in
inflammation, fibrosis, lipid production, and hepatocellular
injury by these medications leads to improvement in fatty
liver disease [80]. However, these medications also play a
role in reducing AGE production and/or RAGE expression,
emphasizing the importance of AGE-RAGE signaling in
initiation and progression of NAFLD [81–85].
As increased production of AGEs, inducing RAGE
production and resulting in activation of AGE-RAGE sig-
naling with its downstream effects at intra- and extracellular
levels appear to be central in the development and pro-
gression of NAFLD, targeting AGE-RAGE signaling with
AGE inhibitor (aminoguanidine), sRAGE (the ligand de-
coy), anti-RAGE antibody, small molecule RAGE antago-
nists aptamers, inhibitors of cytoplasmic domain of RAGE
(ctRAGE), nanocarriers for RAGE siRNA therapy, and/or
inhibitors of the HMGB1-RAGE interaction appear to be
extremely promising and can potentially reduce in-
flammation, improve cell survival, and prevent development
and/or progression of NAFLD [27, 86–89]. AGEs are
structurally modifiedmolecules, which induce inflammation
after its interaction with RAGE, and therefore blocking
AGEs, by means of sRAGE, and can prevent the AGE-RAGE
interaction [23]. However, sRAGE does not cross the blood-
brain barrier and has no significant effects on physical ac-
tivity, appetite, or energy expenditure. Intraperitoneal in-
jection of sRAGE results in significant differences in body
mass between sRAGE versus vehicle-treated high fat-fed
mice. sRAGE could improve insulin sensitivity and reduce
inflammation. Nevertheless, sRAGE has had some limita-
tions in blocking AGEs. It increases the levels of HMGB1
(RAGE ligand) mRNA in the liver tissue of high fat-fed mice
[36]. Heterogeneity of AGEs, accessibility of sRAGE, and
possible loss of beneficial effects of AGE-RAGE signaling by
using sRAGE may further lessen the therapeutic effects of
recombinant sRAGE [79].
Macrophages have a crucial role in initiation and
maintenance of inflammation. In addition, the process of
liver lipotoxicity seems to be caused by accumulation tri-
glyceride-derived material, followed by inflammation and
cellular dysfunction, which needs activity of macrophages
and other immune cells [90]. Free fatty acid can increase
liver macrophage accumulation which technically reiterates
the process of fat accumulation as well [91]. Furthermore,
the process of lobular inflammation in the liver, due to
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inflammatory cell infiltration and secretion of cytokines, can
lead to necrosis and progression of NAFLD to NASH.
However, macrophages are the resident inflammatory cells,
which are involved in initiation and progression of in-
flammation [92].
AGE-RAGE signaling pathway plays an important role
in recruiting macrophages in inflammation and inducing
oxidative stress, but AGEs can increase lipid accumulation in
macrophages, which disables macrophages [25, 79, 93]. In
addition, AGE-RAGE signaling not only participates in
insulin resistance but also seems to have some defensive role,
according to the fact that knocking out RAGE leads to lower
lean mass in high fat diet-fed mice [36]. Furthermore,
sRAGE infusion can alleviate inflammation andmacrophage
phagocytosis [60, 61]. It seems AGE-RAGE signaling
pathway is important for initial activation and phagocytic
Table 1: Clinical studies about AGE/RAGE and NAFLD/NASH in reverse order of the publication year.
Author/Journal and year Participants Results Comments
Palma-Duran et al., Metabolism,
2018 Jun. [67]
50 normoglycemic NAFLD and
58 healthy adults (age, sex, and
BMI matched)
Elevated AGEs/sRAGE ratio was
associated with NAFLD
AGEs (CML) higher, sRAGE
levels lower, and AGEs/sRAGE
ratios were higher in the NAFLD
Mehta et al., PLoS One, 2018 Jun.
[68]
340 obese patients with
metabolic syndrome
Certain polymorphisms of RAGE
gene are indicators of NASH in
obese people
Retrospective study
Only four polymorphisms were
tested
Zelber-Sagi et al., Dig Liver, Dis,
2017 May [63]
55 patients with fatty liver
diagnosed by ultrasound (age
26–64)
sRAGE levels have negative
correlation with liver damage
Serum sRAGE levels have
negative association with fatty
liver and positive correlation
with fiber and vegetables
consumption
Kan et al., J Clin Lab Anal, 2015
Nov. [69]
90 NBNC-HCC
AGE could discriminate NBNC-
HCC from NASH
NBNC-HCC patients had higher
serum levels of AGE, compared
to the NASH and control
subjects
56 NASH
27 control subjects
Santilli et al., Vascular
Pharmacology, 2015 Sep. [70]
110 patients with FCHL, MS, and
both FCHL plus MS
NAFLD patients had significantly
lower plasma esRAGE
irrespective of underlying
metabolic abnormality (FCHL or
MS)
Cross-sectional study
Lower levels of IL-10 and
adiponectin and higher CD40
ligand, endogenous thrombin
potential, and oxidized LDL in
NAFLD patients
Su et al., Medicine (Baltimore),
2015 Aug. [71]
300 cancer-free cases SNP rs1800625 of RAGE gene
increases risk of HCC but has an
inverse association with HCC
progression
5 common polymorphisms of
RAGE gene were tested265 HCC patients
D’Adamo et al., Free Radic Res,
2013 Mar. [72]
Obese prepubertal children with
NAFLD
Vitamin E supplementation
increased the levels of esRAGE
after 6-month treatment Vitamin E could potentially be a
treatment in obese children with
NAFLD
(i) 24 children received vitamin E
supplementation
Vitamin E supplementation
decreased oxidative stress and
improved cardiometabolic
alterations
(ii) 21 age- and sex-matched
received life-style intervention
Gaens et al., Journal of
Hepatology, 2012 Mar. [73] 74 obese individuals
CML and CML upregulated
RAGE-dependent inflammatory
response associated with NAFLD
In vitro model of steatosis used
CML accumulation associated
with increased gene expression
of proinflammatory cytokines
D’Adamo et al., Antioxidants
and Redox signaling, 2011 Mar.
[74]
140 prepubertal obese children esRAGE and sRAGE levels were
significantly lower in obese
prepubertal children affected by
liver steatosis compared with the
group without liver steatosis
Definition of liver steatosis by
ultrasound instead of the gold-
standard invasive liver biopsy
71 boys and 69 girls aged
between 6 and 10 years
Kimura et al., J Gastroenterol,
2010 Jul. [75]
43 patients with dyslipidemia
and biopsy-proven NASH
Atorvastatin reduces the serum
levels of AGEs
AGEs are useful biomarkers for
the attenuation of NASHYilmaz et al., Clin Biochem, 2009
Jun. [76]
40 NASH Patients with NASH (definite
and borderline) had lower
plasma levels of sRAGE
8 borderline NASH
9 simple fatty liver
14 healthy controls
Hyogo et al., J Gastroenterol
Hepatol, 2007 Jul. [77]
66 NASH ,e serum glyceraldehyde-
derived AGE level may be a useful
biomarker for NASH
Constant increase in
glyceraldehyde-derived AGEs
could potentially contribute to
the pathogenesis of NASH
10 simple steatosis
30 controls
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ability of macrophages, but further activity of the pathway
may cause unregulated immune cells activity, such as
macrophages, which ended up having more inflammation
and tissue damage. As a result, transfecting macrophages, as
a resident cell, by sRAGE may not prevent initial activation,
but then after macrophages got activated, sRAGE can be
secreted and probably prevent unregulated stimulation of
immune cells.
Based on the capability of sRAGE in decreasing in-
flammation [60], the important role of macrophages, as a
resident inflammatory cell, in the initiation/modulation of
inflammation, reduction of macrophage phagocytosis
without RAGE [61], and better suppressive effects of secreted
sRAGE on inflammation and cell survival after transfection
of bone marrow mesenchymal stem cells [60] or umbilical
cord-derived mesenchymal stem cells [62], we may propose
that watching diet and autotransplantation of transfected
stem cells, or probably monocytes as a precursor of liver
macrophages, by mutated lentivirus that carries sRAGE
would be a reasonable approach to reduce insulin resistance
and fat deposition in the liver [36, 60, 61]. ,eoretically,
transfected macrophages, with sRAGE, can be activated
initially by being exposed to AGEs. Subsequently, trans-
fected macrophage secretes sRAGE, blocks AGE-RAGE
interaction, inhibits further activation, and reduces in-
flammation, fat deposition, insulin resistance, and hepato-
cytes injury. However, sRAGE has no effect on energy
expenditure or appetite [36], may increase the levels of
HMGB1 mRNA in the liver tissue of high fat-fed mice, and
HMGB1 as a RAGE ligand, and has some roles in the
pathogenesis of liver fibrosis through the RAGE signaling
pathway [36, 67]. On the contrary, the cross-talk between
oxidative stress and AGEs formation, which leads to increase
in the level of AGEs, may limit the effectivity of the sRAGE.
In addition, AGEs are generally complex and heterogenic in
nature, which may diminish the effectivity of sRAGE in
blocking AGE-RAGE interaction [23]. However, the asso-
ciation of certain RAGE gene polymorphisms with NASH
and diabetes may indicate the dominant role of certain AGEs
in the pathophysiology of NASH and diabetes, which brings
up a potential hope to make a sRAGE against the dominant
AGE to be able to block AGE-RAGE interaction [68, 94–96].
8. Conclusion
Autotransplantation of transfected stem cells or monocytes
as a precursor of macrophages or Kupffer cell, with lentivirus
that carries sRAGE, in addition to low carbohydrate/fat diet
may give us promising results in treating NAFLD and its
complications. However, we should consider limitations of
sRAGE, such as accessibility, AGEs heterogeneity, and cross-
talk with other RAGE ligands or oxidative stress, as a po-
tential therapeutic approach.
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[24] R. López-Dı́ez, A. Shekhtman, R. Ramasamy, andA.M. Schmidt,
“Cellular mechanisms and consequences of glycation in ath-
erosclerosis and obesity,” Biochimica et Biophysica Acta (BBA)-
Molecular Basis of Disease, vol. 1862, no. 12, pp. 2244–2252, 2016.
[25] A. M. Schmidt, “2016 ATVB plenary lecture: receptor for
advanced glycation endproducts and implications for the
pathogenesis an treatment of cardiometabolic disorders:
spotlight on the macrophage,” Arteriosclerosis, +rombosis,
and Vascular Biology, vol. 37, pp. 613–621, 2017.
[26] E. Tsai and T.-P. Lee, “Diagnosis and evaluation of non-
alcoholic fatty liver disease/nonalcoholic steatohepatitis, in-
cluding noninvasive biomarkers and transient elastography,”
Clinics in Liver Disease, vol. 22, no. 1, pp. 73–92, 2018.
[27] E. Litwinoff, C. Hurtado Del Pozo, R. Ramasamy, and
A. Schmidt, “Emerging targets for therapeutic development in
diabetes and its complications: the RAGE signaling pathway,”
Clinical Pharmacology and +erapeutics, vol. 98, no. 2,
pp. 135–144, 2015.
[28] Q. Wu, Z.-M. Zhong, S.-Y. Zhu et al., “Advanced oxidation
protein products induce chondrocyte apoptosis via receptor
for advanced glycation end products-mediated, redox-de-
pendent intrinsic apoptosis pathway,”Apoptosis, vol. 21, no. 1,
pp. 36–50, 2016.
[29] J. Liu, J. Mao, Y. Jiang et al., “AGEs induce apoptosis in rat
osteoblast cells by activating the caspase-3 signaling pathway
under a high-glucose environment in vitro,” Applied Bio-
chemistry and Biotechnology, vol. 178, no. 5, pp.1015–1027, 2016.
[30] B. I. Hudson, A. Z. Kalea, M. Del Mar Arriero et al., “In-
teraction of the RAGE cytoplasmic domain with diaphanous-
1 is required for ligand-stimulated cellular migration through
activation of Rac1 and Cdc42,” Journal of Biological Chem-
istry, vol. 283, no. 49, pp. 34457–34468, 2008.
[31] Y. N. Lin and S. Windhorst, “Diaphanous-related formin 1 as
a target for tumor therapy,” Biochemical Society Transactions,
vol. 44, pp. 1289–1293, 2016.
[32] A. Kumar Pasupulati, P. S. Chitra, and G. B. Reddy, “Ad-
vanced glycation end products mediated cellular and mo-
lecular events in the pathology of diabetic nephropathy,”
Biomolecular Concepts, vol. 7, pp. 293–309, 2016.
[33] A. I. Serban, L. Stanca, O. I. Geicu, M. C. Munteanu,
M. Costache, and A. Dinischiotu, “Extracellular matrix is
modulated in advanced glycation end products milieu via a
RAGE receptor dependent pathway boosted by transforming
growth factor-β1,” Journal of Diabetes, vol. 7, no. 1,
pp. 114–124, 2015.
[34] W. Li, W. Ling, X. Teng, C. Quan, S. Cai, and S. Hu, “Effect of
advanced glycation end products, extracellular matrix met-
alloproteinase inducer and matrix metalloproteinases on
type-I collagen metabolism,” Biomedical Reports, vol. 4, no. 6,
pp. 691–693, 2016.
[35] I. Reccia, J. Kumar, C. Akladios et al., “Non-alcoholic fatty
liver disease: a sign of systemic disease,” Metabolism, vol. 72,
pp. 94–108, 2017.
International Journal of Endocrinology 9
[36] F. Song, C. Hurtado del Pozo, R. Rosario et al., “RAGE
regulates themetabolic and inflammatory response to high-fat
feeding in mice,” Diabetes, vol. 63, no. 6, pp. 1948–1965, 2014.
[37] A. Engin, “Non-alcoholic fatty liver disease,” Obesity and
Lipotoxicity, vol. 960, pp. 443–467, 2017.
[38] F. Marra and G. Svegliati-Baroni, “Lipotoxicity and the gut-
liver axis in NASH pathogenesis,” Journal of Hepatology,
vol. 68, no. 2, pp. 280–295, 2018.
[39] R. Patel, S. S. Baker, W. Liu et al., “Effect of dietary advanced
glycation end products on mouse liver,” PLoS One, vol. 7,
no. 4, Article ID e35143, 2012.
[40] S. Zeng, N. Feirt, M. Goldstein et al., “Blockade of receptor for
advanced glycation end product (RAGE) attenuates ischemia
and reperfusion injury to the liver in mice,” Hepatology,
vol. 39, no. 2, pp. 422–432, 2004.
[41] T. Kawai and S. Akira, “,e role of pattern-recognition re-
ceptors in innate immunity: update on Toll-like receptors,”
Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010.
[42] K. Kierdorf and G. Fritz, “RAGE regulation and signaling in
inflammation and beyond,” Journal of Leukocyte Biology,
vol. 94, no. 1, pp. 55–68, 2013.
[43] A. Petrovic, D. Bogojevic, A. Korac et al., “Oxidative stress-
dependent contribution of HMGB1 to the interplay between
apoptosis and autophagy in diabetic rat liver,” Journal of
Physiology and Biochemistry, vol. 73, pp. 511–521, 2017.
[44] L. A. Adams, S. Sanderson, K. D. Lindor, and P. Angulo, “,e
histological course of nonalcoholic fatty liver disease: a lon-
gitudinal study of 103 patients with sequential liver biopsies,”
Journal of Hepatology, vol. 42, no. 1, pp. 132–138, 2005.
[45] V. Ratziu, M. Munteanu, F. Charlotte, L. Bonyhay, and
T. Poynard, “Fibrogenic impact of high serum glucose in chro
nic hepatitis C,” Journal of Hepatology, vol. 39, no. 6,
pp. 1049–1055, 2003.
[46] C. Leung, C. B. Herath, Z. Jia et al., “Dietary advanced gly-
cation end-products aggravate non-alcoholic fatty liver dis-
ease,” World Journal of Gastroenterology, vol. 22, no. 35,
pp. 8026–8040, 2016.
[47] I. A. Leclercq, A. Da Silva Morais, B. Schroyen, N. Van Hul,
and A. Geerts, “Insulin resistance in hepatocytes and sinu-
soidal liver cells: mechanisms and consequences,” Journal of
Hepatology, vol. 47, no. 1, pp. 142–156, 2007.
[48] X. Wei, H. Song, L. Yin et al., “Fatty acid synthesis configures
the plasma membrane for inflammation in diabetes,” Nature,
vol. 539, no. 7628, pp. 294–298, 2016.
[49] H. Unoki and S.-i. Yamagishi, “Advanced glycation end
products and insulin resistance,” Current Pharmaceutical
Design, vol. 14, no. 10, pp. 987–989, 2008.
[50] M. Sharma, S. Mitnala, R. K. Vishnubhotla, R. Mukherjee,
D. N. Reddy, and P. N. Rao, “,e riddle of nonalcoholic fatty
liver disease: progression from nonalcoholic fatty liver to
nonalcoholic steatohepatitis,” Journal of Clinical and Exper-
imental Hepatology, vol. 5, no. 2, pp. 147–158, 2015.
[51] M. Goudarzi, H. Kalantari, andM. Rezaei, “Glyoxal toxicity in
isolated rat liver mitochondria,” Human & Experimental
Toxicology, vol. 37, no. 5, pp. 532–539, 2018.
[52] M. Aragno and R. Mastrocola, “Dietary sugars and endoge-
nous formation of advanced glycation endproducts: emerging
mechanisms of disease,” Nutrients, vol. 9, 2017.
[53] J. J. DiNicolantonio, V. Mehta, N. Onkaramurthy, and
J. H. O’Keefe, “Fructose-induced inflammation and increased
cortisol: a new mechanism for how sugar induces visceral
adiposity,” Progress in Cardiovascular Diseases, vol. 61, no. 1,
pp. 3–9, 2018.
[54] E. A. Muellenbach, C. J. Diehl, M. K. Teachey et al., “In-
teractions of the advanced glycation end product inhibitor
pyridoxamine and the antioxidant α-lipoic acid on insulin
resistance in the obese Zucker rat,”Metabolism, vol. 57, no. 10,
pp. 1465–1472, 2008.
[55] S. K. Biswas, S. Mohtarin, S. R. Mudi et al., “Relationship of
soluble RAGE with insulin resistance and beta cell function
during development of type 2 diabetes mellitus,” Journal of
Diabetes Research, vol. 2015, Article ID 150325, 6 pages, 2015.
[56] R. H. Hassan, O. Bourron, and E. Hajduch, “Defect of insulin
signal in peripheral tissues: important role of ceramide,”
World Journal of Diabetes, vol. 5, no. 3, pp. 244–257, 2014.
[57] V. T. Samuel and G. I. Shulman, “Nonalcoholic fatty liver
disease as a nexus of metabolic and hepatic diseases,” Cell
Metabolism, vol. 27, no. 1, pp. 22–41, 2018.
[58] X.-d. Su, S.-s. Li, Y.-q. Tian, Z.-y. Zhang, G.-z. Zhang, and
L.-x. Wang, “Elevated serum levels of advanced glycation end
products and their monocyte receptors in patients with type 2
diabetes,” Archives of Medical Research, vol. 42, no. 7,
pp. 596–601, 2011.
[59] Q. Wang, G. Zhu, X. Cao, J. Dong, F. Song, and Y. Niu,
“Blocking AGE-RAGE signaling improved functional disor-
ders of macrophages in diabetic wound,” Journal of Diabetes
Research, vol. 2017, Article ID 1428537, 10 pages, 2017.
[60] J. Wang, H. Wang, J. Shi, and Y. Ding, “Effects of bone
marrow MSCs transfected with sRAGE on the intervention of
HMGB1 induced immuno-inflammatory reaction,” In-
ternational Journal of Clinical and Experimental Pathology,
vol. 8, no. 10, pp. 12028–12040, 2015.
[61] M. He, H. Kubo, K. Morimoto et al., “Receptor for advanced
glycation end products binds to phosphatidylserine and as-
sists in the clearance of apoptotic cells,” EMBO Reports,
vol. 12, no. 4, pp. 358–364, 2011.
[62] M. Son, S. Oh, H. Park et al., “Protection against RAGE-
mediated neuronal cell death by sRAGE-secreting human
mesenchymal stem cells in 5xFAD transgenic mouse model,”
Brain, Behavior, and Immunity, vol. 66, pp. 347–358, 2017.
[63] S. Zelber-Sagi, F. Salomone, I. Kolodkin-Gal et al., “Protective
role of soluble receptor for advanced glycation end-products
in patients with non-alcoholic fatty liver disease,” Digestive
and Liver Disease, vol. 49, no. 5, pp. 523–529, 2017.
[64] J. M. Brix, F. Hollerl, H. P. Kopp, G. H. Schernthaner, and
G. Schernthaner, “,e soluble form of the receptor of ad-
vanced glycation endproducts increases after bariatric surgery
in morbid obesity,” International Journal of Obesity, vol. 2012,
no. 36, pp. 1412–1417, 2005.
[65] G. D. Norata, K. Garlaschelli, L. Grigore et al., “Circulating
soluble receptor for advanced glycation end products is in-
versely associated with body mass index and waist/hip ratio in
the general population,” Nutrition, Metabolism and Cardio-
vascular Diseases, vol. 19, no. 2, pp. 129–134, 2009.
[66] K. C. B. Tan, W. S. Chow, A. W. K. Tso et al., “,iazolidi-
nedione increases serum soluble receptor for advanced gly-
cation end-products in type 2 diabetes,” Diabetologia, vol. 50,
no. 9, pp. 1819–1825, 2007.
[67] S. A. Palma-Duran, M. D. Kontogianni, A. Vlassopoulos et al.,
“Serum levels of advanced glycation end-products (AGEs)
and the decoy soluble receptor for AGEs (sRAGE) can identify
non-alcoholic fatty liver disease in age-, sex- and BMI-
matched normo-glycemic adults,” Metabolism, vol. 83,
pp. 120–127, 2018.
[68] R. Mehta, G. Shaw, P. Masschelin et al., “Polymorphisms in
the receptor for advanced glycation end-products (RAGE)
gene and circulating RAGE levels as a susceptibility factor for
10 International Journal of Endocrinology
non-alcoholic steatohepatitis (NASH),” PLoS One, vol. 13,
no. 6, Article ID e0199294, 2018.
[69] H. Kan, S.-i. Yamagishi, A. Ojima et al., “Elevation of serum
levels of advanced glycation end products in patients with
non-B or non-C hepatocellular carcinoma,” Journal of Clin-
ical Laboratory Analysis, vol. 29, no. 6, pp. 480–484, 2015.
[70] F. Santilli, P. Blardi, C. Scapellato et al., “Decreased plasma
endogenous soluble RAGE, and enhanced adipokine secre-
tion, oxidative stress and platelet/coagulative activation
identify non-alcoholic fatty liver disease among patients with
familial combined hyperlipidemia and/or metabolic syn-
drome,” Vascular Pharmacology, vol. 72, pp. 16–24, 2015.
[71] S.-C. Su, M.-J. Hsieh, Y.-E. Chou, W.-L. Fan, C.-B. Yeh, and
S.-F. Yang, “Effects of RAGE gene polymorphisms on the risk
and progression of hepatocellular carcinoma,” Medicine,
vol. 94, no. 34, p. e1396, 2015.
[72] E. D’Adamo, M. L. Marcovecchio, C. Giannini et al., “Im-
proved oxidative stress and cardio-metabolic status in obese
prepubertal children with liver steatosis treated with lifestyle
combined with Vitamin E,” Free Radical Research, vol. 47,
pp. 146–153, 2013.
[73] K. H. J. Gaens, P. M. G. Niessen, S. S. Rensen et al., “En-
dogenous formation of Nε-(carboxymethyl)lysine is increased
in fatty livers and induces inflammatory markers in an in vitro
model of hepatic steatosis,” Journal of Hepatology, vol. 56,
no. 3, pp. 647–655, 2012.
[74] E. D’Adamo, C. Giannini, V. Chiavaroli et al., “What is the
significance of soluble and endogenous secretory receptor for
advanced glycation end products in liver steatosis in obese
prepubertal children?,” Antioxidants and Redox Signaling,
vol. 14, no. 6, pp. 1167–1172, 2011.
[75] Y. Kimura, H. Hyogo, S.-I. Yamagishi et al., “Atorvastatin
decreases serum levels of advanced glycation endproducts
(AGEs) in nonalcoholic steatohepatitis (NASH) patients with
dyslipidemia: clinical usefulness of AGEs as a biomarker for
the attenuation of NASH,” Journal of Gastroenterology,
vol. 45, no. 7, pp. 750–757, 2010.
[76] Y. Yilmaz, E. Ulukaya, O. O. Gul et al., “Decreased plasma
levels of soluble receptor for advanced glycation endproducts
(sRAGE) in patients with nonalcoholic fatty liver disease,”
Clinical Biochemistry, vol. 42, no. 9, pp. 802–807, 2009.
[77] H. Hyogo, S.-I. Yamagishi, K. Iwamoto et al., “Elevated levels
of serum advanced glycation end products in patients with
non-alcoholic steatohepatitis,” Journal of Gastroenterology
and Hepatology, vol. 22, no. 7, pp. 1112–1119, 2007.
[78] K. Asadipooya, “Letter to the editor: “advanced glycation end
products and esRAGE are associated with bone turnover and
incidence of hip fracture in older men”,” +e Journal of
Clinical Endocrinology and Metabolism, vol. 104, no. 3,
pp. 682-683, 2019.
[79] K. Asadipooya and E. M. Uy, “Advanced glycation end-
product, receptor for AGEs, diabetes and bone: review of
literature,” Journal of the Endocrine Society, vol. 3, no. 10,
pp. 1799–1818, 2019.
[80] A. Eshraghian, “Current and emerging pharmacological
therapy for non-alcoholic fatty liver disease,”World Journal of
Gastroenterology, vol. 23, no. 42, pp. 7495–7504, 2017.
[81] G. Brusotti, R. Montanari, D. Capelli et al., “Betulinic acid is a
PPARgamma antagonist that improves glucose uptake, pro-
motes osteogenesis and inhibits adipogenesis,” Scientific Re-
ports, vol. 7, p. 5777, 2017.
[82] K. Byun, Y. Yoo, M. Son et al., “Advanced glycation end-
products produced systemically and by macrophages: a
common contributor to inflammation and degenerative
diseases,” Pharmacology and+erapeutics, vol. 177, pp. 44–55,
2017.
[83] P. Li, Z. Tang, L.Wang, and B. Feng, “Glucagon-like peptide-1
analogue liraglutide ameliorates atherogenesis via inhibiting
advanced glycation end product-induced receptor for ad-
vanced glycosylation end product expression in apolipopro-
tein-E deficient mice,” Molecular Medicine Reports, vol. 16,
no. 3, pp. 3421–3426, 2017.
[84] D.-V. Nguyen, A. Linderholm, A. Haczku, and N. Kenyon,
“Glucagon-like peptide 1: a potential anti-inflammatory
pathway in obesity-related asthma,” Pharmacology and
+erapeutics, vol. 180, pp. 139–143, 2017.
[85] Z. Zhou, Y. Tang, X. Jin et al., “Metformin inhibits advanced
glycation end products-induced inflammatory response in
murine macrophages partly through AMPK activation and
RAGE/NFkappaB pathway suppression,” Journal of Diabetes
Research, vol. 2016, Article ID 4847812, 10 pages, 2016.
[86] S. H. Ku, J. Hong, H.-H. Moon et al., “Deoxycholic acid-
modified polyethylenimine based nanocarriers for RAGE
siRNA therapy in acute myocardial infarction,” Archives of
Pharmacal Research, vol. 38, no. 7, pp. 1317–1324, 2015.
[87] M. B. Manigrasso, J. Pan, V. Rai et al., “Small molecule in-
hibition of ligand-stimulated RAGE-DIAPH1 signal trans-
duction,” Scientific Reports, vol. 6, p. 22450, 2016.
[88] T. Matsui, Y. Higashimoto, Y. Nishino, N. Nakamura,
K. Fukami, and S.-i. Yamagishi, “RAGE-aptamer blocks the
development and progression of experimental diabetic ne-
phropathy,” Diabetes, vol. 66, no. 6, pp. 1683–1695, 2017.
[89] D. Musumeci, G. N. Roviello, and D. Montesarchio, “An
overview on HMGB1 inhibitors as potential therapeutic
agents in HMGB1-related pathologies,” Pharmacology and
+erapeutics, vol. 141, no. 3, pp. 347–357, 2014.
[90] N. Mendez-Sanchez, V. C. Cruz-Ramon, O. L. Ramirez-Perez,
J. P. Hwang, B. Barranco-Fragoso, and J. Cordova-Gallardo,
“New aspects of lipotoxicity in nonalcoholic steatohepatitis,”
International Journal of Molecular Sciences, vol. 19, no. 7,
p. 2034, 2018.
[91] D. B. Harmon, C. Wu, N. Dedousis et al., “Adipose tissue
derived free fatty acids initiate myeloid cell accumulation in
mouse liver in states of lipid oversupply,” American Journal of
Physiology Endocrinology and Metabolism, vol. 315, no. 5, 2018.
[92] Q. M. Anstee, H. L. Reeves, E. Kotsiliti, O. Govaere, and
M. Heikenwalder, “From NASH to HCC: current concepts
and future challenges,” Nature Reviews Gastroenterology and
Hepatology, vol. 16, no. 7, pp. 411–428, 2019.
[93] L. Xu, Y. R. Wang, P. C. Li, and B. Feng, “Advanced glycation
end products increase lipids accumulation in macrophages
through upregulation of receptor of advanced glycation end
products: increasing uptake, esterification and decreasing
efflux of cholesterol,” Lipids in Health and Disease, vol. 15,
no. 1, p. 161, 2016.
[94] W. Cai, J. Li, J. X. Xu et al., “Association of 2184AG poly-
morphism in the RAGE gene with diabetic nephropathy in
Chinese patients with type 2 diabetes,” Journal of Diabetes
Research, vol. 2015, Article ID 310237, , 2015.
[95] P. Kang, C. Tian, and C. Jia, “Association of RAGE gene
polymorphisms with type 2 diabetes mellitus, diabetic reti-
nopathy and diabetic nephropathy,” Gene, vol. 500, no. 1,
pp. 1–9, 2012.
[96] J. Li, W. Cai, W. Zhang et al., “Polymorphism 2184A/G in the
AGER gene is not associated with diabetic retinopathy in Han
Chinese patients with type 2 diabetes,” Journal of In-
ternational Medical Research, vol. 44, no. 3, pp. 520–528, 2016.
International Journal of Endocrinology 11
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
